CRISPR/Cas9-Induced Inactivation of the Autism-Risk Gene

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

1. The emerging paradigms of SETD family enzymes as epigenetic regulators of the immune response in inflammatory diseases.Frontiers in immunology · 2026
   Review
2. Zebrafish mecp2 null-mutation increases anxiety and cortisol levels but no change in adult social preference and larval chemically-induced hyperlocomotion.BMC neuroscience · 2025
   Article
3. Shedding a Light on Dark Genes: A Comparative Expression Study ofGenes · 2024
   Article
4. Epigenetic regulation of craniofacial development and disease.Birth defects research · 2024
   Review
5. Assessing Drug Administration Techniques in Zebrafish Models of Neurological Disease.International journal of molecular sciences · 2023
   Review
6. Moyamoya syndrome in a patient with pathogenic heterozygous variant in theBrain circulation
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors at 4 institutions in 2 countries.

Funding

Abstract

Indexed as